Shares of Neos Therapeutics, Inc. (NASDAQ:NEOS) have been given an average recommendation of “Buy” by the eight ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $15.25.

Several research firms have recently issued reports on NEOS. ValuEngine upgraded shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 12th. Zacks Investment Research upgraded shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, October 31st. Royal Bank Of Canada set a $12.00 target price on shares of Neos Therapeutics and gave the stock an “outperform” rating in a report on Tuesday, August 8th. Cowen restated a “buy” rating on shares of Neos Therapeutics in a report on Thursday, October 26th. Finally, Cantor Fitzgerald set a $20.00 target price on shares of Neos Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 18th.

Neos Therapeutics (NASDAQ:NEOS) remained flat at $$9.25 during trading on Friday. The stock had a trading volume of 254,839 shares, compared to its average volume of 554,059. The company has a quick ratio of 2.14, a current ratio of 2.42 and a debt-to-equity ratio of 4.01. Neos Therapeutics has a 1 year low of $4.85 and a 1 year high of $13.15.

Neos Therapeutics (NASDAQ:NEOS) last released its earnings results on Wednesday, November 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.80) by $0.22. The firm had revenue of $6.70 million during the quarter. Neos Therapeutics had a negative net margin of 339.52% and a negative return on equity of 551.26%. research analysts expect that Neos Therapeutics will post -2.83 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of NEOS. Cortina Asset Management LLC purchased a new position in Neos Therapeutics in the 3rd quarter worth about $5,312,000. Stonepine Capital Management LLC purchased a new position in Neos Therapeutics in the 2nd quarter worth about $4,125,000. Lyon Street Capital LLC purchased a new position in Neos Therapeutics in the 3rd quarter worth about $2,063,000. Russell Investments Group Ltd. increased its stake in Neos Therapeutics by 167.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 270,020 shares of the company’s stock worth $1,971,000 after buying an additional 169,237 shares during the period. Finally, Columbus Circle Investors increased its stake in Neos Therapeutics by 156.2% in the 2nd quarter. Columbus Circle Investors now owns 272,934 shares of the company’s stock worth $1,992,000 after buying an additional 166,414 shares during the period. 45.93% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Analysts Set Neos Therapeutics, Inc. (NEOS) PT at $15.25” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/12/06/analysts-set-neos-therapeutics-inc-neos-pt-at-15-25.html.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Analyst Recommendations for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Stock Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related stocks with our FREE daily email newsletter.